2 minute read

What is Oxbryta?

Oxbryta is a prescription medication developed to help people with sickle cell disease (SCD). It works by improving the oxygen-carrying ability of red blood cells and reducing the complications that come with SCD, like pain crises and organ damage. While it’s been seen as a breakthrough for managing this condition, a recent recall has raised serious concerns about its safety.

What Happened with the Recall?

On December 12, 2024, Global Blood Therapeutics issued a recall for specific batches of Oxbryta after discovering contamination with foreign particles in some of the tablets. The recall affects multiple lots that were distributed across the U.S.  

This is classified as a Class I recall the FDA’s most serious category, meaning the product could cause severe injuries or even death. Patients and healthcare providers have been told to stop using the affected batches immediately.  

What Injuries Can Oxbryta Cause?

The contaminated tablets have been linked to several injuries, including:

• Stomach issues, like nausea, pain, or inflammation from the foreign
• Breathing problems, especially if the particles are inhaled or travel through the
• Organ damage or infections can be especially dangerous for people already dealing with health challenges caused by sickle cell disease.

SCD patients are already vulnerable to health complications, and this contamination only adds to the risks.

How We Can Help

At the Michael Lynch Firm, we’re handling cases for people who’ve been harmed by Oxbryta. If you or someone you care about has been injured, let us fight for you. You may be entitled to compensation for your medical bills, pain, and other damages. Call us at 888-585-5970 or email brandon@mblynchfirm.com for a free consultation.

Date: December 17, 2024

Editor-in-Chief: Brandon Salter

Editor: Sonya Coenen

Citations

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-alerts-patients-about-pfizers-oxbryta-withdrawal-2024-09-26/

https://www.ema.europa.eu/en/news/ema-recommends-suspension-sickle-cell-disease-medicine-oxbryta

https://www.investopedia.com/pfizer-recalls-all-of-its-sickle-cell-disease-treatment-over-safety-concerns-8718725